Get Premium to unlock powerful stock data
NAS:PRTK (USA)  
Paratek Pharmaceuticals Inc logo

Paratek Pharmaceuticals Inc

$ 1.96 +0.03 (+1.55%) 08:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 106.78M
Enterprise V:
$ 284.74M
Volume:
467.82K
Avg Vol (2M):
698.21K
Also Trade In:
Volume:
467.82K
Market Cap $:
106.78M
PE Ratio:
At Loss
Avg Vol (2-Month):
698.21K
Enterprise Value $:
284.74M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Paratek Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Description
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 0.31
Equity-to-Asset -0.83
Debt-to-Equity -1.83
Debt-to-EBITDA -6.42
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -6.36
Distress
Grey
Safe
Beneish M-Score -1.24
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 44.21
9-Day RSI 46.49
14-Day RSI 46.83
6-1 Month Momentum % -58.13
12-1 Month Momentum % -74.03

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.62
Quick Ratio 4.18
Cash Ratio 2.74
Days Inventory 179.35
Days Sales Outstanding 83.56
Days Payable 71.16

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -17

Financials (Next Earnings Date:2022-08-09 Est.)

PRTK's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:PRTK

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 128.901
EPS (TTM) ($) -1.18
Beta 1.26
Volatility % 39.21
14-Day RSI 46.83
14-Day ATR ($) 0.178659
20-Day SMA ($) 2.058
12-1 Month Momentum % -74.03
52-Week Range ($) 1.6 - 7.2703
Shares Outstanding (Mil) 54.48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Paratek Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More